UCB (OTCMKTS:UCBJF) Shares Gap Down - Here's Why

Key Points

• UCB SA shares experienced a significant drop, opening at $235.05 after closing the previous day at $245.64, reflecting a gap down in trading.
• Despite the share price decline, Morgan Stanley has maintained an "overweight" rating for UCB, contributing to a consensus rating of "Buy" from analysts.
• The company has a debt-to-equity ratio of 0.33, indicating a relatively low level of debt compared to equity, alongside strong liquidity ratios with a quick ratio of 0.78.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $245.64, but opened at $235.05. UCB shares last traded at $235.05, with a volume of 516 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reissued an "overweight" rating on shares of UCB in a report on Monday, September 8th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy".

UCB Price Performance

The stock has a 50-day moving average price of $228.21 and a 200 day moving average price of $195.07. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.